Showing 1 - 8 of 8
Various methods have been proposed to address uncertainty in economic evaluations of healthcare programmes. One approach suggested in the literature is to estimate separate confidence intervals for the incremental costs and effects of a new health programme in comparison with an existing...
Persistent link: https://www.econbiz.de/10005449113
Persistent link: https://www.econbiz.de/10005243128
Persistent link: https://www.econbiz.de/10005243160
Cost-effectiveness analysis has been advocated in the health economics methods literature and adopted in a growing number of jurisdictions as an evidence base for decision makers charged with maximising health gains from available resources. This paper critically appraises the information...
Persistent link: https://www.econbiz.de/10005404817
The National Institute for Clinical Excellence (NICE) responds to requests by the Department of Health for guidance on the use of selected new and established technologies in the National Health Service (NHS) in England and Wales. This paper asks whether the NICE methodological guidelines help...
Persistent link: https://www.econbiz.de/10004990353
Neither generic measure detected a gain in HR-QOL as a result of the introduction of an innovative pharmacy-based service. This finding supports other work in the area of pharmacy, where health gains have not changed following interventions. Disease-specific utility measures should be...
Persistent link: https://www.econbiz.de/10011001614
Persistent link: https://www.econbiz.de/10011001748
This paper outlines recent advances in the methods of cost-benefit analysis (CBA). Economic evaluations in healthcare can be criticised for, amongst other things, the inappropriate use of incremental cost-effectiveness ratios and the reporting of benefits in terms of cost savings, such as...
Persistent link: https://www.econbiz.de/10005590453